Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy
- 27 September 2021
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 18 (11) , 677-678
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I TrialJournal of Clinical Oncology, 2021
- Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III StudyJournal of Clinical Oncology, 2021
- Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?Nature Reviews Clinical Oncology, 2021
- Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic LeukemiaInternational Journal of Molecular Sciences, 2020
- Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemiaThe Lancet Oncology, 2019
- Immunotherapy for ALL takes the world by stormNature Reviews Clinical Oncology, 2017
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- The use of intracellular single-chain antibody fragments to inhibit specifically the expression of cell surface moleculesJournal of Immunological Methods, 1996